Pulmatrix Operating Income 2014-2022 | PULM

Pulmatrix operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Pulmatrix Annual Operating Income
(Millions of US $)
2021 $-20
2020 $-10
2019 $-21
2018 $-20
2017 $-17
2016 $-25
2015 $-23
2014 $-9
2014 $-3
2013 $-0
2013 $-1
2012 $-1
Pulmatrix Quarterly Operating Income
(Millions of US $)
2022-03-31 $-5
2021-12-31 $-4
2021-09-30 $-8
2021-06-30 $-4
2021-03-31 $-4
2020-12-31 $-3
2020-09-30 $-1
2020-06-30 $-1
2020-03-31 $-5
2019-12-31 $-4
2019-09-30 $-4
2019-06-30 $-8
2019-03-31 $-5
2018-12-31 $-4
2018-09-30 $-5
2018-06-30 $-6
2018-03-31 $-5
2017-12-31 $-4
2017-09-30 $-4
2017-06-30 $-5
2017-03-31 $-3
2016-12-31 $-7
2016-09-30 $-3
2016-06-30 $-9
2016-03-31 $-5
2015-12-31 $-4
2015-09-30 $-5
2015-06-30 $-11
2015-03-31 $-3
2014-12-31 $-2
2014-09-30 $-3
2014-06-30 $-2
2014-03-31 $-1
2013-12-31 $-1
2013-09-30 $-1
2013-06-30 $-0
2013-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.005B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00